Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252129 · ClinicalTrials.gov registry record · NA
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
A NA study of Lung Cancer and Pathologic Processes, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT06252129: Recruiting NA study of Lung Cancer and Pathologic Processes, sponsored by Brigham and Women's Hospital.
NCT06252129 is a NA study of Lung Cancer and Pathologic Processes that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 160 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06252129, a NA study of Lung Cancer and Pathologic Processes, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.
Primary Outcome
To compare the number of stations and lymph nodes sampled when adopting a standardized technique compared to the conventional (prior) technique.
Conditions Studied
Interventions
- OTHER Control group
- OTHER Subjects undergoing a lung specimen lymph node dissection
Study Locations (1)
Massachusetts
- Brigham and Womens Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT06252129 shows while recruiting
NCT06252129 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Control group is the first listed.
NCT06252129 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06252129 about?
NCT06252129 is a clinical study titled "Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens". Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing ...
What is the current status of trial NCT06252129?
This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2024-07-26. Estimated completion is 2027-12.
What conditions does trial NCT06252129 study?
This clinical trial studies the following conditions: Lung Cancer, Pathologic Processes, Lymph Node Metastasis.
What interventions are being tested in trial NCT06252129?
The interventions under investigation include: Control group (OTHER), Subjects undergoing a lung specimen lymph node dissection (OTHER).
Who is sponsoring clinical trial NCT06252129?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06252129 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06252129's enrollment target sits among peer trials
160 143rd of 409 higher than 266 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI